Dendreon One of the Few Winners Today

Dendreon Corp. (NASDAQ:DNDN) shares managed to move up 7.8% on a dismal day for equities, DNDN shares are now back to $38 per share.

WallStNation.com Sponsors - Become one Today

Over the past 12 months Dendreon Corp (DNDN) shares have traded between $25.78 and its 52-week high of $57.67.  Dendreon shares trade with an EPS of -2.84 and are off 32.51% from its 52-week low.

The reason for the move today -- Dendreon Bringing Provenge to Europe

(TheStreet.com) -- Dendreon(DNDN) will not be required to conduct new clinical trials of its prostate cancer treatment Provenge in order to seek European approval late this year or early in 2012, the company said Friday.

If all goes as planned, Dendreon expects European regulator to approve Provenge to in the first half of 2013. Provenge is a personalized vaccine unique to each prostate cancer patient. To sell the treatment in Europe, Dendreon plans first to hire a contract manufacturer to make Provenge while the company concurrently builds its own European manufacturing facility to be located in Germany.

SOURCE: http://www.thestreet.com/story/10966401/1/dendreon-bringing-provenge-to-europe.html?cm_ven=GOOGLEN#